PRRC2B

Across TCGA pan-cancer cohorts, PRRC2B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRRC2B data layer compared with 23 for mass-spec protein and 13 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PRRC2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRRC2B expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

UCEC, LUAD, and PDAC are the cancer types where PRRC2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	0.981	0.854	.013	24	view →
LUAD	OS	Median	III,IV	1.000	0.661	.004	20	view →
PDAC	OS	Median	II,III,IV	0.272	0.433	.017	8	view →
CCRCC	OS	Median	II,III,IV	0.848	0.626	.012	7	view →
HNSC	DFS	Tertile	IV	0.726	0.956	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRRC2B–UCEC (OS)

Open the UCEC breakdown →